Shock wave therapy to encourage new blood vessels in coronary artery disease
Use of Shock Wave Therapy for Neo-Vascularisation in Non-critical Coronary Artery Disease: Validation by Quantitative Cardiac MRI Perfusion
This will test extracorporeal shock wave therapy to see if it improves blood flow and heart pumping in people with symptomatic coronary artery disease who do not have major blockages.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT07068399 on ClinicalTrials.gov |
What this trial studies
This is a randomized controlled trial that gives cardiac extracorporeal shock wave therapy (CSWT) to one group and compares outcomes to a control group, with measurements taken before and after treatment. The main measures are quantitative myocardial perfusion and left ventricular function using stress contrast cardiac MRI, a non‑radiation method. Participants are adults with symptomatic but non‑obstructive coronary artery disease and left ventricular ejection fraction ≥40%. The trial uses MRI perfusion to provide objective, segmental measures of blood flow that previous CSWT studies mostly assessed with SPECT or PET.
Who should consider this trial
Good fit: Ideal candidates are adults with symptoms of coronary artery disease who do not have obstructive coronary lesions, have LVEF ≥40%, can receive contrast stress cardiac MRI and are not pregnant or otherwise ineligible by the listed exclusions.
Not a fit: Patients with obstructive coronary artery disease, LVEF <40%, recent myocardial infarction, contraindications to contrast stress cardiac MRI or adenosine, severe renal impairment (eGFR <30), or who are hemodynamically unstable are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, CSWT could increase blood flow to under‑perfused heart muscle, reduce angina symptoms, and improve heart pumping, potentially delaying or reducing the need for invasive procedures.
How similar studies have performed: Previous meta-analyses of 39 CSWT reports (about 1,189 patients) found consistent improvements in angina and many reports of better perfusion and left ventricular function by SPECT/PET, but cardiac MRI has not been widely used to confirm those effects.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Patients with symptoms of coronary artery disease * Patients without obstructive coronary artery disease * with LVEF not \< 40%. Exclusion criteria: * Age \< 18 years, * Pregnancy or lactation. * Contraindication to contrast enhanced stress Cardiac Magnetic Resonance (eg. Estimated GFR \<30ml/min/1.73m2, severe allergy to gadolinium based contrast agent, contraindication to adenosine) * Life expectancy \<24 months * Haemodynamically unstable * Participation in other clinical trial within 6 months of enrollment. * Recent myocardial infarction within 6 months. * Unable to consent to or perform components of the study.
Where this trial is running
Hong Kong
- HKU Li Ka Shing Faculty of Medicine — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Ming-Yen NG, BMBS
- Email: myng2@hku.hk
- Phone: 22554524
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.